Jyong Biotech (MENS) Shares Outstanding (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Shares Outstanding (Entity) of $76.0 million for Q4 2025, up 3.63% year-over-year from $73.4 million in Q4 2024, and up 5.95% quarter-over-quarter from $71.8 million in Q2 2025.
Jyong Biotech (MENS) Shares Outstanding (2024 - 2025) Analysis & Trends
Jyong Biotech's Shares Outstanding (Entity) history runs 2 years deep, the most recent figure standing at $76.0 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 3.63% year-over-year to $76.0 million; the TTM figure through Dec 2025 stood at $76.0 million (up 3.63% YoY), while the FY2025 annual figure was $76.0 million, up 3.63% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $76.0 million, up from $71.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $76.0 million in Q4 2025, with the low at $71.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Jyong Biotech | 157.70 Mn | 157.70 Mn | - | 73.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73.01 Mn |
| Jun 30, 2025 | 71.76 Mn |
| Dec 31, 2024 | 71.57 Mn |